<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>药事纵横 | wechat-feeds</title><link>http://MzI5ODI5NDE2OA.favicon.privacyhide.com/favicon.ico</link><description>药事纵横是一个由多位制药精英联合创办的媒体平台，旨在分享与传递药品研发、生产和注册中所涉及的技术、经验和情报，欢迎关注和投稿！投稿请发442015666@qq.com</description><managingEditor> (hellodword)</managingEditor><pubDate>Tue, 23 Feb 2021 12:14:54 +0800</pubDate><image><url>http://MzI5ODI5NDE2OA.favicon.privacyhide.com/favicon.ico</url><title>药事纵横 | wechat-feeds</title><link>http://MzI5ODI5NDE2OA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>从小“国企”到世界巨头，揭秘赛诺菲的40年完美兑变</title><link>https://mp.weixin.qq.com/s/RCeeTqJLvDdiN_fECs6Vqw</link><description></description><content:encoded><![CDATA[从小“国企”到世界巨头，揭秘赛诺菲的40年完美兑变]]></content:encoded><pubDate>Tue, 23 Feb 2021 08:22:18 +0800</pubDate></item><item><title>高效液相检测过程中的质量控制</title><link>https://mp.weixin.qq.com/s/QVe8Uy4lgirKAHAsfadXUg</link><description></description><content:encoded><![CDATA[高效液相检测过程中的质量控制]]></content:encoded><pubDate>Tue, 23 Feb 2021 08:22:18 +0800</pubDate></item><item><title>药事纵横广告投放须知</title><link>https://mp.weixin.qq.com/s/vuA-arqT8T9e3XKvhhX8xQ</link><description></description><content:encoded><![CDATA[药事纵横广告投放须知]]></content:encoded><pubDate>Tue, 23 Feb 2021 08:22:18 +0800</pubDate></item><item><title>粉末直压工艺优势与选择依据</title><link>https://mp.weixin.qq.com/s/wHTQlYsxBjeCrbwAXqOW-Q</link><description></description><content:encoded><![CDATA[粉末直压工艺优势与选择依据]]></content:encoded><pubDate>Sun, 21 Feb 2021 20:46:18 +0800</pubDate></item><item><title>药约课堂|药品注册变更管理研修班第一期（济南3月）</title><link>https://mp.weixin.qq.com/s/WCpthFkejR_MprXejevj6w</link><description></description><content:encoded><![CDATA[药约课堂|药品注册变更管理研修班第一期（济南3月）]]></content:encoded><pubDate>Sun, 21 Feb 2021 20:46:18 +0800</pubDate></item><item><title>修美乐再夺状元，国内TNF-α市场“战局”如何？</title><link>https://mp.weixin.qq.com/s/MfF8WS-k1Q5Nd4l-Tga4tQ</link><description></description><content:encoded><![CDATA[修美乐再夺状元，国内TNF-α市场“战局”如何？]]></content:encoded><pubDate>Sun, 21 Feb 2021 20:46:18 +0800</pubDate></item><item><title>分析方法技术转移的统计学评价</title><link>https://mp.weixin.qq.com/s/gOn79kvtt3hVQVibyrQyIA</link><description></description><content:encoded><![CDATA[分析方法技术转移的统计学评价]]></content:encoded><pubDate>Fri, 19 Feb 2021 21:13:03 +0800</pubDate></item><item><title>创新药物发现史-从提取到半合成，到全合成，再到基于设计的药物发现</title><link>https://mp.weixin.qq.com/s/afPCGy3fo-fDWMvBskv4Ag</link><description></description><content:encoded><![CDATA[创新药物发现史-从提取到半合成，到全合成，再到基于设计的药物发现]]></content:encoded><pubDate>Fri, 19 Feb 2021 21:13:03 +0800</pubDate></item><item><title>药事纵横广告投放须知</title><link>https://mp.weixin.qq.com/s/0kAImPRROgnc1M5YSeRy5A</link><description></description><content:encoded><![CDATA[药事纵横广告投放须知]]></content:encoded><pubDate>Fri, 19 Feb 2021 21:13:03 +0800</pubDate></item><item><title>口服制剂增溶辅料大盘点</title><link>https://mp.weixin.qq.com/s/Wg88QICzSOsE6wQE4p9Ezw</link><description></description><content:encoded><![CDATA[口服制剂增溶辅料大盘点]]></content:encoded><pubDate>Thu, 18 Feb 2021 19:15:56 +0800</pubDate></item><item><title>CMC人士应了解的关于分析方法“生命周期管理”的前世、今生和未来</title><link>https://mp.weixin.qq.com/s/e_fSGGMVre4EkwejVdjx-g</link><description></description><content:encoded><![CDATA[CMC人士应了解的关于分析方法“生命周期管理”的前世、今生和未来]]></content:encoded><pubDate>Thu, 18 Feb 2021 19:15:56 +0800</pubDate></item><item><title>人人学懂免疫学：第十九期</title><link>https://mp.weixin.qq.com/s/SyhAMaqw1HrKqt0wYu2GTQ</link><description></description><content:encoded><![CDATA[人人学懂免疫学：第十九期]]></content:encoded><pubDate>Thu, 18 Feb 2021 19:15:56 +0800</pubDate></item><item><title>扑热息痛，你不知道的痛</title><link>https://mp.weixin.qq.com/s/croeAF56ktG5jj8_d-oOow</link><description></description><content:encoded><![CDATA[扑热息痛，你不知道的痛]]></content:encoded><pubDate>Thu, 18 Feb 2021 10:54:28 +0800</pubDate></item><item><title>关于溶出方法耐用性的一些思考</title><link>https://mp.weixin.qq.com/s/p9pRSDR9CBWpNa2FB90ngQ</link><description></description><content:encoded><![CDATA[关于溶出方法耐用性的一些思考]]></content:encoded><pubDate>Thu, 18 Feb 2021 10:54:28 +0800</pubDate></item><item><title>FDA批准新型CDK4/6抑制剂用于小细胞肺癌化疗辅助，以减小骨髓抑制风险</title><link>https://mp.weixin.qq.com/s/iXw-mR-WPlyYjzjPIZuqOA</link><description></description><content:encoded><![CDATA[FDA批准新型CDK4/6抑制剂用于小细胞肺癌化疗辅助，以减小骨髓抑制风险]]></content:encoded><pubDate>Sun, 14 Feb 2021 09:47:03 +0800</pubDate></item><item><title>新公众号“药海书香”，期待各位大佬的关注</title><link>https://mp.weixin.qq.com/s/85N_Wvj35wdJqf9E3dsp4A</link><description></description><content:encoded><![CDATA[新公众号“药海书香”，期待各位大佬的关注]]></content:encoded><pubDate>Sun, 14 Feb 2021 09:47:03 +0800</pubDate></item><item><title>FDA批准再生元的新型降脂药evinacumab</title><link>https://mp.weixin.qq.com/s/zWXdxkpeYdkMRu7uGtODZg</link><description></description><content:encoded><![CDATA[FDA批准再生元的新型降脂药evinacumab]]></content:encoded><pubDate>Sat, 13 Feb 2021 10:06:20 +0800</pubDate></item><item><title>新公众号“药海书香”，期待各位大佬的关注</title><link>https://mp.weixin.qq.com/s/5u1U0o_GgkajfzArYIC3DA</link><description></description><content:encoded><![CDATA[新公众号“药海书香”，期待各位大佬的关注]]></content:encoded><pubDate>Sat, 13 Feb 2021 10:06:20 +0800</pubDate></item><item><title>药事纵横向各位读者拜年了</title><link>https://mp.weixin.qq.com/s/o6bNfn7vGRda3JnSaXdFDg</link><description></description><content:encoded><![CDATA[药事纵横向各位读者拜年了]]></content:encoded><pubDate>Fri, 12 Feb 2021 11:42:58 +0800</pubDate></item><item><title>FDA批准umbralisib用于边缘区淋巴瘤和滤泡淋巴瘤治疗</title><link>https://mp.weixin.qq.com/s/g7CJ9elH5VvtBPaOD5hz2g</link><description></description><content:encoded><![CDATA[FDA批准umbralisib用于边缘区淋巴瘤和滤泡淋巴瘤治疗]]></content:encoded><pubDate>Wed, 10 Feb 2021 15:47:08 +0800</pubDate></item></channel></rss>